5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | NEUTRAL | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 64.21▼ | 64.29▼ | 64.28▼ | 64.69▼ | 63.71▲ |
MA10 | 64.25▼ | 64.28▼ | 64.32▼ | 64.29▼ | 61.60▲ |
MA20 | 64.27▼ | 64.29▼ | 64.58▼ | 64.42▼ | 57.01▲ |
MA50 | 64.32▼ | 64.65▼ | 64.32▼ | 61.57▲ | 51.84▲ |
MA100 | 64.31▼ | 64.26▼ | 64.16▼ | 56.52▲ | 48.76▲ |
MA200 | 64.49▼ | 64.27▼ | 63.48▲ | 53.42▲ | 36.73▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.017▼ | 0.009▲ | -0.061▼ | -0.172▼ | 0.665▲ |
RSI | 37.538▼ | 42.742▼ | 44.850▼ | 54.473▲ | 64.073▲ |
STOCH | 41.622 | 46.528 | 46.111 | 68.675 | 85.366▲ |
WILL %R | -83.871▼ | -76.190▼ | -62.745 | -41.844 | -12.342▲ |
CCI | -146.804▼ | -51.538 | -34.527 | 14.262 | 90.238 |
Thursday, August 14, 2025 05:59 AM
Clene ( ($CLNN) ) has issued an update. On August 13, 2025, Clene Inc. announced amendments to its December 2024 senior secured convertible ...
|
Thursday, August 14, 2025 05:38 AM
The Company plans to hold an end-of-Phase 2 Type B meeting with the FDA in the third quarter of 2025. This meeting will review results from the Phase 2 VISIONARY-MS trial and discuss the planned Phase ...
|
Wednesday, August 13, 2025 04:14 AM
NYSE:CNM 1 Year Share Price vs Fair Value Explore Core & Main's Fair Values from the Community and select yours ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 64.74 | 64.76 | 63.93 | 64.12 | 2,096,800 |
14/08/25 | 64.89 | 65.05 | 63.74 | 64.51 | 2,504,500 |
13/08/25 | 65.46 | 65.77 | 64.74 | 65.66 | 2,688,350 |
12/08/25 | 63.94 | 65.515 | 63.86 | 65.47 | 2,030,400 |
11/08/25 | 63.56 | 63.94 | 62.75 | 63.71 | 1,266,900 |
08/08/25 | 64.22 | 64.41 | 63.37 | 63.96 | 1,394,198 |
07/08/25 | 64.20 | 65.00 | 63.74 | 64.10 | 1,775,633 |
06/08/25 | 64.08 | 64.325 | 63.38 | 63.54 | 930,714 |
05/08/25 | 63.91 | 64.38 | 62.89 | 64.04 | 1,470,957 |
04/08/25 | 63.02 | 63.87 | 62.56 | 63.82 | 1,236,134 |
|
|
||||
|
|
||||
|
|